Baseline characteristics of the CASTING Study population: a Phase IIIB Trial evaluating Ocrelizumab in patients with relapsing-remitting Multiple Sclerosis and suboptimal response to disease-modifying therapies


Vermersch P., Comi G., Siva A., Oreja-Guevara C., Wiendl H., Van Wijmeersch B., ...Daha Fazla

4th Congress of the European-Academy-of-Neurology (EAN), Lisbon, Portekiz, 16 - 19 Haziran 2018, cilt.25, ss.190 identifier

  • Cilt numarası: 25
  • Basıldığı Şehir: Lisbon
  • Basıldığı Ülke: Portekiz
  • Sayfa Sayıları: ss.190